Corbus Pharmaceuticals Company Insiders
| CRBP Stock | USD 37.16 3.96 9.63% |
Corbus Pharmaceuticals' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Corbus Pharmaceuticals Holding suggests that virtually all insiders are extremely bullish. Corbus Pharmaceuticals employs about 19 people. The company is managed by 22 executives with a total tenure of roughly 90 years, averaging almost 4.0 years of service per executive, having 0.86 employees per reported executive.
| Yuval Cohen CEO CEO and Director |
| Mark Tepper President Co-Founder and President and Chief Scientific Officer |
Corbus Pharmaceuticals' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-03-07 | Cormorant Asset Management, Lp | Acquired 250000 @ 40.05 | View | ||
| 2024-02-02 | Cormorant Asset Management, Lp | Acquired 750000 @ 19 | View | ||
| 2024-01-26 | Cormorant Asset Management, Lp | Acquired 282632 @ 32.24 | View |
Monitoring Corbus Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Corbus |
Corbus Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Corbus Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Corbus will maintain a workforce of slightly above 19 employees by May 2024.Corbus Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.5957) % which means that it has lost $0.5957 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4198) %, meaning that it created substantial loss on money invested by shareholders. Corbus Pharmaceuticals' management efficiency ratios could be used to measure how well Corbus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Corbus Pharmaceuticals' Return On Capital Employed is relatively stable compared to the past year. As of 04/17/2024, Return On Equity is likely to grow to 6.78, while Return On Tangible Assets are likely to drop (1.66). As of 04/17/2024, Liabilities And Stockholders Equity is likely to grow to about 50.5 M, while Total Current Liabilities is likely to drop slightly above 16.9 M.As of 04/17/2024, Common Stock Shares Outstanding is likely to drop to about 2.9 M. In addition to that, Net Loss is likely to drop to about (40 M)
Corbus Pharmaceuticals Workforce Comparison
Corbus Pharmaceuticals Holding is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 1,401. Corbus Pharmaceuticals claims roughly 19.0 in number of employees contributing just under 2% to equities under Health Care industry.
Corbus Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Corbus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Corbus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Corbus Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 1.0 | 1 | 1 | 1,787 | 1,787 |
| 2024-03-01 | 16.5 | 33 | 2 | 1,918,686 | 7,808 |
| 2020-12-01 | 0.6667 | 4 | 6 | 182,273 | 356,066 |
| 2019-09-01 | 2.0 | 6 | 3 | 120,814 | 120,000 |
| 2018-12-01 | 1.0 | 1 | 1 | 10,000 | 10,000 |
| 2018-06-01 | 11.0 | 11 | 1 | 437,311 | 220,000 |
| 2017-03-01 | 7.0 | 7 | 1 | 748,733 | 20,000 |
| 2016-09-01 | 8.0 | 8 | 1 | 307,460 | 20,000 |
| 2015-12-01 | 16.0 | 16 | 1 | 21,085 | 375.00 |
| 2015-09-01 | 9.0 | 27 | 3 | 193,050 | 240,000 |
| 2015-06-01 | 7.0 | 7 | 1 | 95,650 | 50,000 |
| 2014-12-01 | 1.4091 | 31 | 22 | 104,662 | 1,993,791 |
Corbus Pharmaceuticals Notable Stakeholders
A Corbus Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Corbus Pharmaceuticals often face trade-offs trying to please all of them. Corbus Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Corbus Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Yuval Cohen | CEO and Director | Profile | |
| Mark Tepper | Co-Founder and President and Chief Scientific Officer | Profile | |
| Robert Discordia | Vice President Pharmaceutical Development & Manufacturing | Profile | |
| Sean Moran | CFO | Profile | |
| Ted Jenkins | Senior Director, Investor Relations and Communications | Profile | |
| John Jenkins | Director | Profile | |
| Alan Holmer | Independent Director | Profile | |
| Renu Gupta | Independent Director | Profile | |
| Avery Catlin | Independent Director | Profile | |
| David Hochman | Director | Profile | |
| Sergei Atamas | Executive Director - Research | Profile | |
| Rachelle Jacques | Director | Profile | |
| Paris Panayiotopoulos | Director | Profile | |
| MD MA | Chief Officer | Profile | |
| Craig Millian | Chief Commercial Officer | Profile | |
| CPA MBA | Chief Officer | Profile | |
| Lindsey Smith | Head Advocacy | Profile | |
| Scott Constantine | Director Operations | Profile | |
| Craig MBA | Chief Officer | Profile | |
| Christina Bertsch | Head Resources | Profile | |
| Barbara White | Chief Medical Officer | Profile | |
| Rachael Brake | Chief Officer | Profile |
About Corbus Pharmaceuticals Management Performance
The success or failure of an entity such as Corbus Pharmaceuticals often depends on how effective the management is. Corbus Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Corbus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Corbus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.58) | (1.66) | |
| Return On Capital Employed | 12.45 | 13.07 | |
| Return On Assets | (1.58) | (1.66) | |
| Return On Equity | 6.46 | 6.78 |
The data published in Corbus Pharmaceuticals' official financial statements usually reflect Corbus Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Corbus Pharmaceuticals. For example, before you start analyzing numbers published by Corbus accountants, it's critical to develop an understanding of what Corbus Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Corbus Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Corbus Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Corbus Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Corbus Pharmaceuticals Holding. Please utilize our Beneish M Score to check the likelihood of Corbus Pharmaceuticals' management manipulating its earnings.
Corbus Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Corbus Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Corbus Pharmaceuticals within its industry.Corbus Pharmaceuticals Manpower Efficiency
Return on Corbus Pharmaceuticals Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2.3M | |
| Net Loss Per Executive | 2M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Corbus Pharmaceuticals information on this page should be used as a complementary analysis to other Corbus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Corbus Stock analysis
When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Corbus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corbus Pharmaceuticals. If investors know Corbus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corbus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.31) | Quarterly Revenue Growth (1.00) | Return On Assets (0.60) | Return On Equity (3.42) |
The market value of Corbus Pharmaceuticals is measured differently than its book value, which is the value of Corbus that is recorded on the company's balance sheet. Investors also form their own opinion of Corbus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Corbus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corbus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Corbus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corbus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corbus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corbus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.